Skip to main content
. 2017 Mar 23;8(3):e2700. doi: 10.1038/cddis.2017.113

Table 3. The ongoing clinical trials on R428 in cancers.

Identifiers Start date Cancers Time frame Phase Status
NCT02922777 November 2016 Non-small cell lung carcinoma 42 days Phase 1 Recruiting
NCT02488408 September 2014 Acute myeloid leukaemia 15 months Phase 1 Recruiting
NCT02424617 March 2015 Non-small cell lung cancer 3 months Phase 1/2 Recruiting
NCT02872259 September 2016 Melanoma An average of 1 year Phase 1/2 Not yet recruiting

Ongoing clinical trials of R428 in various cancer types